| Multiple Sclerosis, Relapsing-Remitting
Ponvory vs Copaxone
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, relapsing-remitting.Deep comparison between: Ponvory vs Copaxone with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCopaxone has a higher rate of injection site reactions vs Ponvory based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Copaxone but not Ponvory, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ponvory
Copaxone
At A Glance
Oral
Once daily
S1P receptor 1 modulator
SC injection
Daily or 3x weekly
Immunomodulator
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- active secondary progressive multiple sclerosis
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, active secondary progressive multiple sclerosis Initiate with 14-day oral dose titration starting at 2 mg once daily per schedule; maintenance dose is 20 mg orally once daily beginning Day 15.
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive 20 mg/mL SC once daily OR 40 mg/mL SC three times per week (at least 48 hours apart); the two strengths are not interchangeable.
Contraindications
- Myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
- Known hypersensitivity to glatiramer acetate or mannitol, including anaphylaxis
Adverse Reactions
Most common (>=10%) Upper respiratory tract infection, hepatic transaminase elevation, hypertension
Serious Infections, bradyarrhythmia and AV conduction delays, respiratory effects, liver injury, increased blood pressure, cutaneous malignancies, macular edema, posterior reversible encephalopathy syndrome, severe increase in disability after stopping
Most common (>=2%) Injection site erythema, pain, pruritus, mass, edema, and inflammation; vasodilatation, rash, dyspnea, chest pain, nausea, palpitations, lymphadenopathy, asthenia, anxiety, infection
Serious Anaphylactic reactions, immediate post-injection reaction, chest pain, lipoatrophy and skin necrosis, potential effects on immune response, hepatic injury
Postmarketing Sepsis, SLE syndrome, thrombosis, myocardial infarct, thrombocytopenia, lymphoma-like reaction, acute leukemia, cirrhosis, hepatic injury, anaphylactic reactions, cerebrovascular accident, pulmonary embolus, blindness
Pharmacology
Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1 and blocks lymphocyte egress from lymph nodes, reducing peripheral blood lymphocyte counts; the therapeutic mechanism in multiple sclerosis may involve reduction of lymphocyte migration into the central nervous system.
Glatiramer acetate is an immunomodulator thought to act by modifying immune processes responsible for MS pathogenesis; upon SC administration, glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ponvory
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (10/12)
Copaxone
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (1/12) · Qty limit (11/12)
UnitedHealthcare
Ponvory
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Copaxone
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Ponvory
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Copaxone
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PonvoryView full Ponvory profile
CopaxoneView full Copaxone profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.